← Anika Therapeutics, Inc. ANIK
Market Price
$21.91
Market Cap
$281.68M
P/E Ratio
N/A
Revenue (FY 2025)
↓-5.9% YoY
$112.82M
3-Yr CAGR: -10.3%
Net Income
↑80.7% YoY
-$10.88M
Net Margin: -9.6%
Free Cash Flow
↑287.1% YoY
$4.36M
FCF Yield: 1.55%
EPS (Diluted)
↑80.2% YoY
$-0.76
Basic: $-0.76
Return on Equity
Efficiency
-7.6%
ROA: -320.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ANIK)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $103.4M | — | $79.4M | $32.5M | — | $2.15 | — | $23.8M | $9.8M | — |
| FY 2017 | $113.4M | +9.7% | $86.1M | $31.8M | -2.2% | $2.11 | -1.9% | $40.8M | $31.8M | +225.2% |
| FY 2018 | $105.6M | -6.9% | $74.3M | $18.7M | -41.2% | $1.27 | -39.8% | $34.9M | $30.3M | -4.9% |
| FY 2019 | $114.6M | +8.6% | $85.9M | $27.2M | +45.2% | $1.89 | +48.8% | $37.0M | $34.2M | +12.9% |
| FY 2020 | $130.5M | +13.8% | $69.0M | $-24.0M | -188.2% | $-1.69 | -189.4% | $13.1M | $11.4M | -66.5% |
| FY 2021 | $147.8M | +13.3% | $82.9M | $4.1M | +117.2% | $0.28 | +116.6% | $8.4M | $3.3M | -71.5% |
| FY 2022 | $156.2M | +5.7% | $93.6M | $-14.9M | -459.4% | $-1.02 | -464.3% | $4.4M | $-3.1M | -194.6% |
| FY 2023 | $166.7M | +6.7% | $103.1M | $-82.7M | -456.3% | $-5.64 | -452.9% | $-1.8M | $-7.2M | -134.5% |
| FY 2024 | $119.9M | -28.1% | $76.0M | $-56.4M | +31.8% | $-3.83 | +32.1% | $5.4M | $-2.3M | +67.7% |
| FY 2025 | $112.8M | -5.9% | $63.8M | $-10.9M | +80.7% | $-0.76 | +80.2% | $11.2M | $4.4M | +287.1% |
Valuation
Market Price
$21.91
Market Cap
$281.68M
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
2.03
FCF Yield
1.55%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
56.56%
Operating Margin
-9.80%
Net Margin
-9.64%
Return on Equity (ROE)
-7.58%
Return on Assets (ROA)
-320.00%
Asset Turnover
33.18x
Revenue 3-Yr CAGR
-10.28%
Financial Health & Liquidity
Current Ratio
0.21
Cash Ratio
3.62
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$57.48M
Total Debt
N/A
Book Value / Share
$10.78
Cash Flow Efficiency
Operating Cash Flow
$11.19M
Capital Expenditures (CapEx)
$6.83M
Free Cash Flow
$4.36M
OCF / Revenue
9.92%
FCF / Revenue
3.87%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$-0.76
EPS (Basic)
$-0.76
Dividends / Share
N/A
Book Value / Share
$10.78
EPS YoY Growth
80.16%
Balance Sheet (FY 2025)
Total Assets
$3.40M
Total Liabilities
$15.87M
Stockholders' Equity
$143.47M
Current Assets
$3.40M
Current Liabilities
$15.87M